<DOC>
	<DOCNO>NCT00999882</DOCNO>
	<brief_summary>The main purpose study establish safe dose AZD8055 patient mild moderate liver disease provide information potential side effect drug may cause collect data hepatocellular carcinoma respond drug .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics ( PK ) Preliminary Efficacy Tor Kinase Inhibitor Liver Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Advanced stage Hepatocellular Carcinoma ( HCC ) confirm cytology histology Advanced stage Hepatocellular Carcinoma ( HCC ) metastatic Hepatocellular Carcinoma ( HCC ) inoperable incurable standard available treatment Relatively good overall health cancer ( WHO performance status ( 02 ) Patients severe heart condition , heart surgery coronary artery bypass graft within last 6 month , patient uncontrolled high blood pressure despite medical management . Patients must receive anti cancer therapy include TACE within 21 day enter trial Patients must receive liver transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>mTor Kinase Inhibitor</keyword>
	<keyword>Phase I/II</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Hepatocellular carcinoma ( HCC )</keyword>
	<keyword>Asia</keyword>
	<keyword>HCC</keyword>
	<keyword>Safety pharmacokinetics</keyword>
</DOC>